VNZ/TEZ/D-IVA
Phase 3Small molecule
Vertex PharmaceuticalsVNZ/TEZ/D-IVA is one of 52 small molecule programs targeting Statin. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
107 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
Biaxin
AbbViePhase 2
Lamprene
NovartisPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Amoxil
GGlobal Antibiotics Research and Development Partnership
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trimethoprim-Sulfamethoxazole
AstellasPhase 2
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VX-121/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Statin1 trial
Adult1 trial
Cystic Fibrosis1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VNZ/TEZ/D-IVA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company